Navigation Links
Osteoporosis Drugs: right time to take-off

Millions of Indians are at risk of developing osteoporosis. While women are more likely to develop the disease, men are equal sufferers from it. It is estimated that at the age of 50, a woman has a 40 per cent chance of developing an osteoporotic fracture during her remaining lifetime. Drugs, which are used to treat osteoporosis, can be grouped into two classes. The first category comprises agents, which limit the rate of bone loss and are referred to as ‘‘anti-resorption drugs’’. The second group of drugs promotes bone formation and is referred to as ‘‘bone forming drugs’’.

// No single class of drugs is perceived to manage osteoporosis on a standalone basis. Hormone Replacement Therapy (HRT) and bisphosphonates are the most prescribed drugs. Calcium, vitamins and alfacalcidol preparations are also prescribed for prevention. The anti-osteoporosis market includes multinationals like Glaxo-Smithkline, Novartis, Infar and Wyeth Lederle. The Indian companies who have notched up a substantial market share are Cipla, Dr Reddy’s Laboratories and Elder Pharmaceuticals.

The Indian osteoporosis medications market presents great opportunity. Indian pharmaceutical companies need to increase awareness levels about the disease and it’s implications on both the physician as well as patient level. New compounds that rebuild bone mass and are associated with minimal side effects represent another area of opportunity. Currently, Selective Oestrogen Receptors Modulators (SERMs) such as Raloxifene and new generation bisphosphonates such as Risedronate have not been introduced in the Indian market. These drugs have a better efficacy and fewer side effects than the current therapies.

The osteoporosis medications market is viewed as a typical lifestyle related disease with high brand loyalty. Current lifestyle disease markets like cardiovascular and diabetes therapies are gradually getting saturated. The time is right for Indian pharmaceutical companies to focus on the osteoporosis medications market. br>

'"/>




Related medicine news :

1. New treatment for Osteoporosis
2. Osteoporosis in men
3. Fluoride Found Effective in Osteoporosis
4. Mutation connected to Osteoporosis
5. Osteoporosis associated with Childhood Cancer
6. A treatment for Osteoporosis
7. Osteoporosis could be caused by irregular periods
8. Back exercises reduces Osteoporosis
9. Osteoporosis and kidney stones gene marker identified
10. The Answer To Prevent Osteoporosis
11. Blood Tests Can Help Detect Osteoporosis Early In Life
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/26/2017)... ... February 26, 2017 , ... ... lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der ... , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements for ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... wholesale distribution in North America, today announced it would be offering some it’s ... which prides itself on crafting quality and unique baby clothing/feeding products, will team ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... standard in staffing, scheduling, and reporting for healthcare organizations. This comprehensive and ... the entire staffing process. StaffBridge technology improves staffing efficiency, maximizes resource allocation, ...
(Date:2/26/2017)... Florida (PRWEB) , ... February 26, 2017 , ... ... (PD) patients after receiving cognitive rehabilitation, according to a study released today at ... known that cognitive rehabilitation programs are proven to be effective in improving cognitive ...
(Date:2/25/2017)... ... 25, 2017 , ... FCPX users now have the ability to sharpen a ... ProSharpen Color users have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, ... spectrum tools users can visually see the color range effected with ease all within ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , Israel and TAMPA, Fla. , ... an emerging medical device company focused on developing ... procedures, applauds the members of the FDA,s Circulatory ... for their acknowledgement of the need for cerebral ... "The statements shared by this FDA ...
(Date:2/27/2017)... 2017 Now in its seventh year, ... are most successful at developing and commercialising innovation. ... The Index can ... molecule to two different companies in early phase, which would ... objective analysis of each company,s performance between 2011 and 2016, the 2017 ...
(Date:2/27/2017)... Period October – December 2016 ... to SEK -16.4 (-6.4) million Result after tax amounted to ... after dilution Cash flow from operating activities amounted to SEK ... Period full ... Operating result amounted to SEK -39.5 (-29.5) million ...
Breaking Medicine Technology: